Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Mar 31, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Total Revenue
502,069
454,443
461,097
--
Cost of Revenue
111,374
95,899
96,949
--
Gross Profit
390,695
358,544
364,148
--
Operating Expenses
Research Development
142,257
172,812
172,963
--
Selling General and Administrative
187,295
187,900
170,112
--
Non Recurring
--
--
--
--
Others
15,677
16,994
17,063
--
Total Operating Expenses
345,229
377,706
360,138
--
Operating Income or Loss
45,466
(19,162)
4,010
--
Income from Continuing Operations
Total Other Income/Expenses Net
57,557
11,100
3,409
--
Earnings Before Interest And Taxes
108,267
(3,360)
16,098
--
Interest Expense
6,915
6,421
6,276
--
Income Before Tax
101,352
(9,781)
9,822
--
Income Tax Expense
19,971
(24,805)
(45,214)
--
Minority Interest
--
--
--
--
Net Income From Continuing Ops
81,381
15,024
55,036
--
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
--
Net Income
81,381
15,024
55,036
--
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
81,381
15,024
55,036
--

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information